ophthalmologyОфтальмологияOphthalmology in Russia1816-50952500-0845Ophthalmology10.18008/1816-5095-2026-3-536-542ophthalmology-3058Research ArticleОБЗОРЫREVIEWSРоль ингибиторов фактора роста эндотелия сосудов в лечении болезни Коатса. Обзор литературыThe Role of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Coats’ Disease. Literature Reviewhttps://orcid.org/0000-0001-6523-5191ДемченкоЕ. Н.DemchenkoE. N.

Демченко Елена Николаевна, кандидат медицинских наук, научный сотрудник отдела патологии глаз у детей 

ул. Садовая-Черногрязская, 14/19, Москва, 105062

Demchenko Elena N., PhD, researcher of the Department of children’s ocular pathology 

Sadovaya-Chernogryazskaya str., 14/19, Moscow, 105062

https://orcid.org/0000-0003-3735-6249ДенисоваЕ. В.DenisovaE. V.

Денисова Екатерина Валерьевна, кандидат медицинских наук, старший научный сотрудник отдела патологии глаз у детей

ул. Садовая-Черногрязская, 14/19, Москва, 105062

Denisova Ekaterina V., PhD, senior researcher of the Department of children’s ocular pathology 

Sadovaya-Chernogryazskaya str., 14/19, Moscow, 105062

ФГБУ «Научный медицинский исследовательский центр глазных болезней имени Гельмгольца»РоссияHelmgoltz National Medical Research Centre of Eye DiseasesRussian Federation202605102026233536542Copyright © Демченко Е.Н., Денисова Е.В., 20262026Демченко Е.Н., Денисова Е.В.Demchenko E.N., Denisova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.ophthalmojournal.com/opht/article/view/3058

В обзоре проанализированы данные имеющихся в доступных источниках 57 оригинальных исследований о применении ингибиторов фактора роста эндотелия сосудов в лечении болезни Коатса (БК). Установлено, что интравитреальное введение ингибиторов ангиогенеза является простым, эффективным и безопасным дополнительным методом лечения тяжелых стадий БК, рефрактерного макулярного отека и неоваскуляризации 3-го типа. Однако, учитывая вариабельность клинических проявлений, схем лечения и ограниченное количество наблюдений, необходимы дальнейшие исследования для определения четких показаний и оптимальных схем анти-VEGF терапии при данном заболевании.

The review analyzes data from 57 original studies available in accessible sources on the use of vascular endothelial growth factor inhibitors in the treatment of Coats’ disease (CD). It has been established that intravitreal administration of angiogenesis inhibitors is a simple, effective and safe additional method for the treatment of severe stages of CD, refractory macular edema and type 3 neovascularization. However, given the variability of clinical presentations, treatment regimens and limited number of observations, further studies are needed to determine clear indications and optimal anti-VEGF therapy regimens for this disease.

болезнь Коатсалазеркоагуляциякриокоагуляцияингибиторы фактора роста эндотелия сосудовин- травитреальное введениетелеангиэктазииэкссудативная отслойка сетчаткиCoats diseaselaser coagulationcryocoagulationvascular endothelial growth factor inhibitorsintravitreal administrationtelangiectasiaexudative retinal detachmentReferencesCoats G. Forms of retinal dysplasia with massive exudation. R Lond Ophthalmol Hosp Rep. 1908;17:440–525.Coats G. Forms of retinal dysplasia with massive exudation. R Lond Ophthalmol Hosp Rep. 1908;17:440–525.Демченко ЕН, Денисова ЕВ, Коголева ЛВ, Белова МВ, Осипова НА. Эффективность лазерной коагуляции у детей с болезнью Коатса. Российская педиатрическая офтальмология. 2022:17(3):5-13. https://doi.org/10.17816/rpoj108456.Demchenko EN, Denisova EV, Kogoleva LV, Belova MV, Osipova NA. The effectiveness of laser coagulation in children with Coats’ disease. Russian Pediatric Ophthalmology. 2022:17(3):5-13 (In Russ.). https://doi.org/10.17816/rpoj108456.Shields CL, Udyaver S, Dalvin LA, Lim LAS, Atalay HT, Khoo CTL, et al. Coats disease in 351 eyes: Analysis of features and outcomes over 45 years (by decade) at a single center. Indian J Ophthalmol. 2019;67(6):772–783. doi: 10.4103/ijo.IJO_449_19.Shields CL, Udyaver S, Dalvin LA, Lim LAS, Atalay HT, Khoo CTL, et al. Coats disease in 351 eyes: Analysis of features and outcomes over 45 years (by decade) at a single center. Indian J Ophthalmol. 2019;67(6):772–783. doi: 10.4103/ijo.IJO_449_19.Morris B, Foot B, Mulvihill A. A population-based study of Coats disease in the United Kingdom I: epidemiology and clinical features at diagnosis. Eye (Lond). 2010;24(12):1797–1801. doi: 10.1038/eye.2010.126.Morris B, Foot B, Mulvihill A. A population-based study of Coats disease in the United Kingdom I: epidemiology and clinical features at diagnosis. Eye (Lond). 2010;24(12):1797–1801. doi: 10.1038/eye.2010.126.Charles PLF, Lee SYS, Brundler M-A, Scott CM, Parulekar MV. Coats disease in a 3-week-old boy J AAPOS. 2014;18(1):86–88. doi: 10.1016/j.jaapos.2013.08.013.Charles PLF, Lee SYS, Brundler M-A, Scott CM, Parulekar MV. Coats disease in a 3-week-old boy J AAPOS. 2014;18(1):86–88. doi: 10.1016/j.jaapos.2013.08.013.Rishi E, Rishi P, Appukuttan B, Uparkar M, Sharma T, Gopal L. Coats’ disease of adultonset in 48 eyes. Indian J Ophthalmol. 2016 Jul;64(7):518–523. doi: 10.4103/03014738.190141.Rishi E, Rishi P, Appukuttan B, Uparkar M, Sharma T, Gopal L. Coats’ disease of adultonset in 48 eyes. Indian J Ophthalmol. 2016 Jul;64(7):518–523. doi: 10.4103/03014738.190141.Smithen LM, Brown GC, Brucker AJ, Yannuzzi LA, Klais CM, Spaide RF. Coats’ disease diagnosed in adulthood. Ophthalmology. 2005;112(6):1072–1078. doi: 10.1016/j.ophtha.2004.12.038.Smithen LM, Brown GC, Brucker AJ, Yannuzzi LA, Klais CM, Spaide RF. Coats’ disease diagnosed in adulthood. Ophthalmology. 2005;112(6):1072–1078. doi: 10.1016/j.ophtha.2004.12.038.Dalvin LA, Udyaver S, Lim L-AS, Mazloumi M, Atalay HT, Khoo CTL, Shields CL. Coats disease: clinical features and outcomes by age category in 351 cases. Journal of Pediatric Ophthalmology & Strabismus. 2019;56(5):288–296. doi: 10.3928/0191391320190716-01.Dalvin LA, Udyaver S, Lim L-AS, Mazloumi M, Atalay HT, Khoo CTL, Shields CL. Coats disease: clinical features and outcomes by age category in 351 cases. Journal of Pediatric Ophthalmology & Strabismus. 2019;56(5):288–296. doi: 10.3928/0191391320190716-01.Коголева ЛВ, Иванова МС, Демченко ЕН, Судовская ТВ, Бобровская ЮА, Кокоева НШ, Макарова АА. Особенности клинических проявлений, течения и результаты лечения ретинита Коатса у детей. Российский офтальмологический журнал. 2023;16(1):41-46. https://doi.org/10.21516/2072-0076-2023-16-1-41-46.Kogoleva LV, Ivanova MS, Demchenko EN, Sudovskaya TV, Bobrovskaya JA, Kokoeva NSh, Makarova AA. Clinical manifestation, course and treatment results of Coats disease in children. Russian Ophthalmological Journal. 2023;16(1):41-46 (In Russ.). https://doi.org/10.21516/2072-0076-2023-16-1-41-46.Shields JA, Shields CL, Honavar SG, Demirci H, Cater J. Classification and management of Coats disease: the 2000 Proctor Lecture. Am J Ophthalmol. 2001;131(5):572–583. doi: 10.1016/s0002-9394(01)00896-0.Shields JA, Shields CL, Honavar SG, Demirci H, Cater J. Classification and management of Coats disease: the 2000 Proctor Lecture. Am J Ophthalmol. 2001;131(5):572–583. doi: 10.1016/s0002-9394(01)00896-0.Yang X, Wang C, Su G. Recent advances in the diagnosis and treatment of Coats’ disease. Int Ophthalmol. 2019;39(4):957–970. doi: 10.1007/s10792-019-01095-8.Yang X, Wang C, Su G. Recent advances in the diagnosis and treatment of Coats’ disease. Int Ophthalmol. 2019;39(4):957–970. doi: 10.1007/s10792-019-01095-8.Shapiro MJ, Chow CC, Karth PA, Kiernan DF, Blai MP. Effects of green diode laser in the treatment of pediatric Coats disease. Am J Ophthalmol. 2011;151(4):725– 731.e2. doi: 10.1016/j.ajo.2010.10.024.Shapiro MJ, Chow CC, Karth PA, Kiernan DF, Blai MP. Effects of green diode laser in the treatment of pediatric Coats disease. Am J Ophthalmol. 2011;151(4):725– 731.e2. doi: 10.1016/j.ajo.2010.10.024.Karacorlu M, Hocaoglu M, Muslubas IS, Arf S. Long-term anatomical and functional outcomes following vitrectomy for advanced coats disease. Retina. 2017;37(9):1757–1764. doi: 10.1097/IAE.0000000000001415.Karacorlu M, Hocaoglu M, Muslubas IS, Arf S. Long-term anatomical and functional outcomes following vitrectomy for advanced coats disease. Retina. 2017;37(9):1757–1764. doi: 10.1097/IAE.0000000000001415.Li AS, Capone A, Trese MT, Sears JE, Kychenthal A, De la Huerta I, Ferrone PJ. Long-term outcomes of total exudative retinal detachments in stage 3B Coats disease. Ophthalmology. 2018;125(6):887–893. doi: 10.1016/j.ophtha.2017.12.010.Li AS, Capone A, Trese MT, Sears JE, Kychenthal A, De la Huerta I, Ferrone PJ. Long-term outcomes of total exudative retinal detachments in stage 3B Coats disease. Ophthalmology. 2018;125(6):887–893. doi: 10.1016/j.ophtha.2017.12.010.Rishi P, Rishi E, Attiku Y, Uparkar M, Bhende P, Bhende M, Sen P. Surgical management of advanced Coats disease in 32 eyes: a 20-year study. J Vitreoretin Dis. 2020;4(6):467–471. doi: 10.1177/2474126420930504.Rishi P, Rishi E, Attiku Y, Uparkar M, Bhende P, Bhende M, Sen P. Surgical management of advanced Coats disease in 32 eyes: a 20-year study. J Vitreoretin Dis. 2020;4(6):467–471. doi: 10.1177/2474126420930504.Suesskind D, Altpeter E, Schrader M, Bartz-Schmidt KU, Aisenbrey S. Pars plana vitrectomy for treatment of advanced Coats’ disease-presentation of a modified surgical technique and long-term follow-up. Graefes Arch Clin Exp Ophthalmol. 2014;252(6):873–879. doi: 10.1007/s00417-013-2512-3.Suesskind D, Altpeter E, Schrader M, Bartz-Schmidt KU, Aisenbrey S. Pars plana vitrectomy for treatment of advanced Coats’ disease-presentation of a modified surgical technique and long-term follow-up. Graefes Arch Clin Exp Ophthalmol. 2014;252(6):873–879. doi: 10.1007/s00417-013-2512-3.He Y-G, Wang H, Zhao B., Lee J., Bahl D, McCluske J. Elevated vascular endothelial growth factor level in Coats’ disease and possible therapeutic role of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2010;248(10):1519–1521. doi: 10.1007/s00417010-1366-1.He Y-G, Wang H, Zhao B., Lee J., Bahl D, McCluske J. Elevated vascular endothelial growth factor level in Coats’ disease and possible therapeutic role of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2010;248(10):1519–1521. doi: 10.1007/s00417010-1366-1.Kase S, Rao NA, Yoshikawa H, Fukuhara J, Noda K, Kanda A, Ishida S. Expression of vascular endothelial growth factor in eyes with Coats’ disease. Invest Ophthalmol Vis Sci. 2013;54:57–62. doi: 10.1167/iovs.12-10613.Kase S, Rao NA, Yoshikawa H, Fukuhara J, Noda K, Kanda A, Ishida S. Expression of vascular endothelial growth factor in eyes with Coats’ disease. Invest Ophthalmol Vis Sci. 2013;54:57–62. doi: 10.1167/iovs.12-10613.Mano F, Matsushita I, Kondo H, Utamura S, Kondo C, Kusaka S. Vitrectomy and external drainage of subretinal fluid containing high concentration of vascular endothelial growth factor for advanced coats disease. Sci Rep. 2021;11(1):19333. doi: 10.1038/s41598-021-98968-9.Mano F, Matsushita I, Kondo H, Utamura S, Kondo C, Kusaka S. Vitrectomy and external drainage of subretinal fluid containing high concentration of vascular endothelial growth factor for advanced coats disease. Sci Rep. 2021;11(1):19333. doi: 10.1038/s41598-021-98968-9.Sun Y, Jain A, Moshfeghi DM. Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium. Graefes Arch Clin Exp Ophthalmol. 2007;245:1387–1388. doi: 10.1007/s00417-007-0559-8.Sun Y, Jain A, Moshfeghi DM. Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium. Graefes Arch Clin Exp Ophthalmol. 2007;245:1387–1388. doi: 10.1007/s00417-007-0559-8.Zhang H, Liu Z.-L. Increased nitric oxide and vascular endothelial growth factor levels in the aqueous humor of patients with coats’ disease. J Ocul Pharmacol Ther. 2012;28(4):397–401. doi: 10.1089/jop.2011.0168.Zhang H, Liu Z.-L. Increased nitric oxide and vascular endothelial growth factor levels in the aqueous humor of patients with coats’ disease. J Ocul Pharmacol Ther. 2012;28(4):397–401. doi: 10.1089/jop.2011.0168.Zhao Q, Peng XY, Chen FH, Zhang YP, Wang L, You QS, Jonas JB. Vascular endothelial growth factor in Coats’ disease. Acta Ophthalmol. 2014;92(3):e225–228. doi: 10.1111/aos.12158.Zhao Q, Peng XY, Chen FH, Zhang YP, Wang L, You QS, Jonas JB. Vascular endothelial growth factor in Coats’ disease. Acta Ophthalmol. 2014;92(3):e225–228. doi: 10.1111/aos.12158.Zheng XX, Jiang YR. The effect of intravitreal bevacizumab injection as the initial treatment for Coats’ disease. Graefes Arch Clin Exp Ophthalmol. 2014;252:35–42. doi: 10.1007/s00417-013-2409-1.Zheng XX, Jiang YR. The effect of intravitreal bevacizumab injection as the initial treatment for Coats’ disease. Graefes Arch Clin Exp Ophthalmol. 2014;252:35–42. doi: 10.1007/s00417-013-2409-1.Нероева НВ, Танковский ВЕ, Пономарева СИ. Инфекционный статус пациентов с болезнью Коатса. Российский офтальмологический журнал. 2025;18(1):43–47. doi: 10.21516/2072-0076-2025-18-1-43-47.Neroeva NV, Tankovskiy VE, Ponomareva SI. The infectious status of patients with Coats disease. Russian ophthalmological journal. 2025;18(1):43–47 (In Russ.). doi: 10.21516/2072-0076-2025-18-1-43-47.Alvarez-Rivera LG, Abraham-Marín ML, Flores-Orta HJ, Mayorquín-Ruiz M, CortésLuna CF. Coat’s disease treated with bevacizumab (Avastin). [Article in Spanish]. Arch Soc Esp Oftalmol. 2008;83(5):329–331. doi: 10.4321/s0365-66912008000500010.Alvarez-Rivera LG, Abraham-Marín ML, Flores-Orta HJ, Mayorquín-Ruiz M, CortésLuna CF. Coat’s disease treated with bevacizumab (Avastin). [Article in Spanish]. Arch Soc Esp Oftalmol. 2008;83(5):329–331. doi: 10.4321/s0365-66912008000500010.Böhm MRR, Uhlig CE. Use of intravitreal triamcinolone and bevacizumab in Coats’ disease with central macular edema. Graefes Arch Clin Exp Ophthalmol. 2011;249(7):1099–1101. doi: 10.1007/s00417-011-1629-5.Böhm MRR, Uhlig CE. Use of intravitreal triamcinolone and bevacizumab in Coats’ disease with central macular edema. Graefes Arch Clin Exp Ophthalmol. 2011;249(7):1099–1101. doi: 10.1007/s00417-011-1629-5.Cackett P, Wong D, Cheung CMG. Combined intravitreal bevacizumab and argon laser treatment for Coats’ disease. Acta Ophthalmol. 2010;88(2):e48–49. doi: 10.1111/j.1755-3768.2009.01514.x.Cackett P, Wong D, Cheung CMG. Combined intravitreal bevacizumab and argon laser treatment for Coats’ disease. Acta Ophthalmol. 2010;88(2):e48–49. doi: 10.1111/j.1755-3768.2009.01514.x.Cakir M, Cekiç O, Yilmaz OF. Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease. J AAPOS. 2008;12(3):309–311. doi: 10.1016/j.jaapos.2008.01.009.Cakir M, Cekiç O, Yilmaz OF. Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease. J AAPOS. 2008;12(3):309–311. doi: 10.1016/j.jaapos.2008.01.009.Entezari M, Ramezani A, Safavizadeh L, Bassirnia N. Resolution of macular edema in Coats’ disease with intravitreal bevacizumab. Indian J Ophthalmol. 2010;58(1):80–82. doi: 10.4103/0301-4738.58482.Entezari M, Ramezani A, Safavizadeh L, Bassirnia N. Resolution of macular edema in Coats’ disease with intravitreal bevacizumab. Indian J Ophthalmol. 2010;58(1):80–82. doi: 10.4103/0301-4738.58482.Fiorentzis M, Stavridis E, Seitz B, Viestenz A. Adjuvant anti-VEGF therapy in Coats’ disease. [Article in German]. Ophthalmologe. 2015;112(5):451–454. doi: 10.1007/s00347-014-3122-0.Fiorentzis M, Stavridis E, Seitz B, Viestenz A. Adjuvant anti-VEGF therapy in Coats’ disease. [Article in German]. Ophthalmologe. 2015;112(5):451–454. doi: 10.1007/s00347-014-3122-0.Jun JH, Kim YC, Kim KS. Resolution of severe macular edema in adult coats’ disease with intravitreal triamcinolone and bevacizumab injection. Korean J Ophthalmol. 2008;22(3):190–193. doi: 10.3341/kjo.2008.22.3.190.Jun JH, Kim YC, Kim KS. Resolution of severe macular edema in adult coats’ disease with intravitreal triamcinolone and bevacizumab injection. Korean J Ophthalmol. 2008;22(3):190–193. doi: 10.3341/kjo.2008.22.3.190.Kaul S, Uparkar M, Mody K, Walinjkar J, Kothari M, Natarajan S. Intravitreal antivascular endothelial growth factor agents as an adjunct in the management of Coats’ disease in children. Indian J Ophthalmol. 2010;58(1):76–78. doi: 10.4103/03014738.58480.Kaul S, Uparkar M, Mody K, Walinjkar J, Kothari M, Natarajan S. Intravitreal antivascular endothelial growth factor agents as an adjunct in the management of Coats’ disease in children. Indian J Ophthalmol. 2010;58(1):76–78. doi: 10.4103/03014738.58480.Kim J, Park KH, Woo SJ. Combined photodynamic therapy and intravitreal bevacizumab injection for the treatment of adult Coats’ disease: a case report. Korean J Ophthalmol. 2010;24(6):374–376. doi: 10.3341/kjo.2010.24.6.374.Kim J, Park KH, Woo SJ. Combined photodynamic therapy and intravitreal bevacizumab injection for the treatment of adult Coats’ disease: a case report. Korean J Ophthalmol. 2010;24(6):374–376. doi: 10.3341/kjo.2010.24.6.374.Kodama A, Sugioka K, Kusaka S, Matsumoto C, Shimomura Y. Combined treatment for Coats’ disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases. BMC Ophthalmol. 2014 Mar 25:14:36. doi: 10.1186/1471-2415-14-36.Kodama A, Sugioka K, Kusaka S, Matsumoto C, Shimomura Y. Combined treatment for Coats’ disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases. BMC Ophthalmol. 2014 Mar 25:14:36. doi: 10.1186/1471-2415-14-36.Lin C-J, Hwang J-F, Chen Y-T, Chen S-N. The effect of intravitreal bevacizumab in the treatment of Coats disease in children. Retina. 2010;30(4):617–622. doi: 10.1097/IAE.0b013e3181c2e0b7.Lin C-J, Hwang J-F, Chen Y-T, Chen S-N. The effect of intravitreal bevacizumab in the treatment of Coats disease in children. Retina. 2010;30(4):617–622. doi: 10.1097/IAE.0b013e3181c2e0b7.Patel NA, Berrocal AM, Murray TG, Villegas VM. Advanced Coats’ disease treated with intravitreal brolucizumab combined with laser photocoagulation. Am J Ophthalmol Case Rep. 2020 2:19:100815. doi: 10.1016/j.ajoc.2020.100815.Patel NA, Berrocal AM, Murray TG, Villegas VM. Advanced Coats’ disease treated with intravitreal brolucizumab combined with laser photocoagulation. Am J Ophthalmol Case Rep. 2020 2:19:100815. doi: 10.1016/j.ajoc.2020.100815.Raoof N, Quhill F. Successful use of intravitreal bevacizumab and pascal laser photocoagulation in the management of adult Coats’ disease. Middle East Afr J Ophthalmol. 2013;20(3):256–258. doi: 10.4103/0974-9233.114805.Raoof N, Quhill F. Successful use of intravitreal bevacizumab and pascal laser photocoagulation in the management of adult Coats’ disease. Middle East Afr J Ophthalmol. 2013;20(3):256–258. doi: 10.4103/0974-9233.114805.Stergiou PK, Symeonidis C, Dimitrakos SA. Coats’ disease: treatment with intravitreal bevacizumab and laser photocoagulation. Acta Ophthalmol. 2009;87(6):687– 688. doi: 10.1111/j.1755-3768.2008.01253.x.Stergiou PK, Symeonidis C, Dimitrakos SA. Coats’ disease: treatment with intravitreal bevacizumab and laser photocoagulation. Acta Ophthalmol. 2009;87(6):687– 688. doi: 10.1111/j.1755-3768.2008.01253.x.Teh SS, Ahem A, Bastion M-LC. Intravitreal ranibizumab in the management of stage 2B Coats disease in a young adult Malay man. BMJ Case Rep. 2013 16: 2013:bcr2013009697. doi: 10.1136/bcr-2013-009697.Teh SS, Ahem A, Bastion M-LC. Intravitreal ranibizumab in the management of stage 2B Coats disease in a young adult Malay man. BMJ Case Rep. 2013 16: 2013:bcr2013009697. doi: 10.1136/bcr-2013-009697.Theoulakis PE, Halki A, Petropoulos IK, Katsimpris JM. Coats disease in a 14-year-old boy treated with intravitreal ranibizumab and retinal laser photocoagulation. Klin Monbl Augenheilkd. 2012;229(4):447–450. doi: 10.1055/s0031-1299216.Theoulakis PE, Halki A, Petropoulos IK, Katsimpris JM. Coats disease in a 14-year-old boy treated with intravitreal ranibizumab and retinal laser photocoagulation. Klin Monbl Augenheilkd. 2012;229(4):447–450. doi: 10.1055/s0031-1299216.Venkatesh P, Mandal S, Garg S. Management of Coats disease with bevacizumab in 2 patients. Can J Ophthalmol. 2008;43(2):245 –246. doi: 10.3129/i08-028.Venkatesh P, Mandal S, Garg S. Management of Coats disease with bevacizumab in 2 patients. Can J Ophthalmol. 2008;43(2):245 –246. doi: 10.3129/i08-028.Waite K, Ng E, Bennett MD. Anti-VEGF as adjunctive therapy for Coats disease. Retina today. April 2010.Waite K, Ng E, Bennett MD. Anti-VEGF as adjunctive therapy for Coats disease. Retina today. April 2010.Wang KY, Cheng CK. A combination of intravitreal bevacizumab injection with tunable argon yellow laser photocoagulation as a treatment for adult-onset Coats’ disease. J Ocul Pharmacol Ther. 2011;27:525–530. doi: 10.1089/jop.2011.0088.Wang KY, Cheng CK. A combination of intravitreal bevacizumab injection with tunable argon yellow laser photocoagulation as a treatment for adult-onset Coats’ disease. J Ocul Pharmacol Ther. 2011;27:525–530. doi: 10.1089/jop.2011.0088.Zhao T, Wang K, Ma Y, Jiang Y-R. Resolution of total retinal detachment in Coats’ disease with intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2011;249(11):1745–1746. doi: 10.1007/s00417-010-1563-y.Zhao T, Wang K, Ma Y, Jiang Y-R. Resolution of total retinal detachment in Coats’ disease with intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2011;249(11):1745–1746. doi: 10.1007/s00417-010-1563-y.Galliard MC, Mataftsi A, Balmer A, Houghton S, Munier FL. Ranibizumab in the management of advanced Coats disease stages 3B and 4. Retina. 2014;34(11):2275– 2281. doi: 10.1097/IAE.0000000000000248.Galliard MC, Mataftsi A, Balmer A, Houghton S, Munier FL. Ranibizumab in the management of advanced Coats disease stages 3B and 4. Retina. 2014;34(11):2275– 2281. doi: 10.1097/IAE.0000000000000248.Jiang L, Qin B, Luo X-L, Cao H, Deng T-M, Yang M-M, Meng T, Yang H-Q. Three-year follow-up of Coats disease treated with conbercept and 532-nm laser photocoagulation. World J Clin Cases. 2020;8(24):6243–6251. doi: 10.12998/wjcc.v8.i24.6243.Jiang L, Qin B, Luo X-L, Cao H, Deng T-M, Yang M-M, Meng T, Yang H-Q. Three-year follow-up of Coats disease treated with conbercept and 532-nm laser photocoagulation. World J Clin Cases. 2020;8(24):6243–6251. doi: 10.12998/wjcc.v8.i24.6243.Li L, Li S, Liu J, Deng G, Ma J, Lu H. Long-term efficacy and complications of intravitreal anti-vascular endothelial growth factor agents combined with ablative therapies in juvenile Coats disease: a five year follow-up study. Graefes Arch Clin Exp Ophthalmol. 2023. doi: 10.1007/s00417-023-06162-6.Li L, Li S, Liu J, Deng G, Ma J, Lu H. Long-term efficacy and complications of intravitreal anti-vascular endothelial growth factor agents combined with ablative therapies in juvenile Coats disease: a five year follow-up study. Graefes Arch Clin Exp Ophthalmol. 2023. doi: 10.1007/s00417-023-06162-6.Li S, Deng G, Liu J, Ma Y, Lu H. The effects of a treatment combination of antiVEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat’s disease. BMC Ophthalmol. 2017;17(1):76. doi: 10.1186/s12886-017-0469-4.Li S, Deng G, Liu J, Ma Y, Lu H. The effects of a treatment combination of antiVEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat’s disease. BMC Ophthalmol. 2017;17(1):76. doi: 10.1186/s12886-017-0469-4.Park S, Cho HJ, Lee DW, Kim CG, Kim JW. Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats’ disease. Graefes Arch Clin Exp Ophthalmol. 2016;254(8):1511–1517. doi: 10.1007/s00417-015-3233-6.Park S, Cho HJ, Lee DW, Kim CG, Kim JW. Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats’ disease. Graefes Arch Clin Exp Ophthalmol. 2016;254(8):1511–1517. doi: 10.1007/s00417-015-3233-6.Ramasubramanian A, Shields CL. Bevacizumab for Coats’ disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol. 2012;96(3):356–359. doi: 10.1136/bjophthalmol-2011-300141.Ramasubramanian A, Shields CL. Bevacizumab for Coats’ disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol. 2012;96(3):356–359. doi: 10.1136/bjophthalmol-2011-300141.Ray R, Barañano DE, Hubbard GB. Treatment of Coats’ disease with intravitreal bevacizumab. Br J Ophthalmol. 2013;97(3):272–277. doi: 10.1136/bjophthalmol-2012-302250.Ray R, Barañano DE, Hubbard GB. Treatment of Coats’ disease with intravitreal bevacizumab. Br J Ophthalmol. 2013;97(3):272–277. doi: 10.1136/bjophthalmol-2012-302250.Sein J, Tzu JH, Murray TG, Berrocal AM. Treatment of Coats’ disease with combination therapy of intravitreal bevacizumab, laser photocoagulation, and sub-tenon corticosteroids. Ophthalmic Surg Lasers Imaging Retina. 2016;47:443–449. doi: 10.3928/23258160-20160419-07.Sein J, Tzu JH, Murray TG, Berrocal AM. Treatment of Coats’ disease with combination therapy of intravitreal bevacizumab, laser photocoagulation, and sub-tenon corticosteroids. Ophthalmic Surg Lasers Imaging Retina. 2016;47:443–449. doi: 10.3928/23258160-20160419-07.Stanga PE, Jaberansari H, Bindra MS, Martinez MG, Biswas S. Transcleral drainage of subretinal fluid, anti-vascular endothelial growth factor, and wide-field imagingguided laser in coats exudative retinal detachment. Retina. 2016;36(1):156–162. doi: 10.1097/IAE.0000000000000669.Stanga PE, Jaberansari H, Bindra MS, Martinez MG, Biswas S. Transcleral drainage of subretinal fluid, anti-vascular endothelial growth factor, and wide-field imagingguided laser in coats exudative retinal detachment. Retina. 2016;36(1):156–162. doi: 10.1097/IAE.0000000000000669.Villegas VM, Gold AS, Berrocal AM, Murray TG. Advanced Coats’ disease treated with intravitreal bevacizumab combined with laser vascular ablation. Clin Ophthalmol. 2014:8:973–976. doi: 10.2147/OPTH.S62816.Villegas VM, Gold AS, Berrocal AM, Murray TG. Advanced Coats’ disease treated with intravitreal bevacizumab combined with laser vascular ablation. Clin Ophthalmol. 2014:8:973–976. doi: 10.2147/OPTH.S62816.Yang Q, Wei W, Shi X, Yang L. Successful use of intravitreal ranibizumab injection and combined treatment in the management of Coats’ disease. Acta Ophthalmol. 2016;94(4):401–406. doi: 10.1111/aos.13067.Yang Q, Wei W, Shi X, Yang L. Successful use of intravitreal ranibizumab injection and combined treatment in the management of Coats’ disease. Acta Ophthalmol. 2016;94(4):401–406. doi: 10.1111/aos.13067.Zhang L, Ke Y, Wang W, Shi X, Hei K, Li X. The efficacy of conbercept orranibizumab intravitreal injection combined with laser therapy for Coats’ disease. Graefes Arch Clin Exp Ophthalmol. 2018;256(7):1339–1346. doi: 10.1007/s00417-018-3949-1.Zhang L, Ke Y, Wang W, Shi X, Hei K, Li X. The efficacy of conbercept orranibizumab intravitreal injection combined with laser therapy for Coats’ disease. Graefes Arch Clin Exp Ophthalmol. 2018;256(7):1339–1346. doi: 10.1007/s00417-018-3949-1.Adeniran JF, Duff SМ, Mimouni M, Lambert N, Ramasubramanian A. Treatment of Coats’ disease: an analysis of pooled results. Int J Ophthalmol. 2019 18;12(4):668– 674. doi: 10.18240/ijo.2019.04.23.Adeniran JF, Duff SМ, Mimouni M, Lambert N, Ramasubramanian A. Treatment of Coats’ disease: an analysis of pooled results. Int J Ophthalmol. 2019 18;12(4):668– 674. doi: 10.18240/ijo.2019.04.23.

The authors declare that there are no conflicts of interest present.